LY 3127804

Drug Profile

LY 3127804

Alternative Names: LY3127804

Latest Information Update: 22 Apr 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 09 Nov 2015 Preclinical trials in Solid tumours in USA (IV) before November 2015
  • 09 Nov 2015 Eli Lilly plans a phase I trial for Solid tumours including Gastric cancer or Gastro-oesophageal junction adenocarcinoma, Hepatocellular carcinoma (Monotherapy, Combination therapy, Metastatic disease) in USA, France, Spain and Belgium (IV) (NCT02597036)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top